Retatrutide
The next generation of weight loss treatment — targeting three metabolic pathways for potentially the most effective medical weight management yet
What Makes Retatrutide Different?
The first triple-action weight loss medication, targeting three metabolic receptors simultaneously.
Targets GLP-1, GIP, and glucagon receptors simultaneously — more pathways than any existing treatment
Phase 2 trials showed up to 24% body weight reduction in just 48 weeks — surpassing all current treatments
The glucagon receptor increases energy expenditure, meaning you burn more calories at rest — a first for weight loss medications
Substantial reductions in liver fat observed, relevant for non-alcoholic fatty liver disease (NAFLD)
Developed by the same company behind Mounjaro, with decades of expertise in metabolic treatments
CLINICAL EVIDENCE
Phase 2 Trial Results
Published in the New England Journal of Medicine, the results exceeded expectations.
Average body weight reduction at the highest dose after 48 weeks
Average weight lost by participants on the highest dose
Of participants lost at least 5% of their body weight
Of participants lost at least 15% of their body weight
For context, Wegovy achieves ~15% weight loss over 68 weeks and Mounjaro ~22% over 72 weeks. Retatrutide achieved 24% in just 48 weeks — and the weight loss curve had not yet plateaued.
How Does Retatrutide Compare?
The key differentiator: retatrutide doesn’t just reduce appetite — it also increases energy expenditure.
| Wegovy (Semaglutide) | Mounjaro (Tirzepatide) | Retatrutide (Coming Soon) | |
|---|---|---|---|
| Mechanism | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Average Weight Loss | ~15% | ~22% | ~24% |
| Administration | Weekly injection | Weekly injection | Weekly injection |
| UK Availability | Available now | Available now | Expected 2027–2028 |
| Burns More Calories | — | — | Yes |
| Evernu Price | From £169/mo | From £229/mo | TBC |
When Will Retatrutide Be Available?
Evernu will offer retatrutide to eligible patients as soon as it receives UK regulatory approval.
Phase 2 Trials Complete
Results published in the New England Journal of Medicine with up to 24% weight loss achieved
Phase 3 Trials Underway
Large-scale trials with thousands of participants currently running worldwide including European sites
2026–2027: Regulatory Submission
Submissions expected to the FDA, MHRA, and EMA following Phase 3 results
2027–2028: UK Availability
Anticipated MHRA approval and availability through licensed UK pharmacies
Available at Evernu
As soon as retatrutide is approved, Evernu will offer it as part of our comprehensive weight loss programme
No Need to Wait
Both Mounjaro and Wegovy are available now through Evernu and produce outstanding results. Many patients achieve life-changing weight loss with current treatments, supported by our programme of nutritional guidance, exercise support, and ongoing clinical monitoring.
When retatrutide becomes available, existing Evernu patients will be among the first assessed for eligibility.
Start Your Free AssessmentMeet Your Expert Team
Dr. Michael Gough
Medical Director
Over 15 years of clinical experience in preventative medicine and metabolic health.
Noel Smyth
Chief Health Coach
Certified health coach specialising in behavioural change and lifestyle medicine.
Joseph Smyth
Care Team Lead
Leads our care team, ensuring exceptional support from consultation through treatment.
Frequently Asked Questions
Retatrutide is a next-generation weight loss medication that targets three metabolic receptors simultaneously: GLP-1, GIP, and glucagon. This triple-action mechanism represents a significant advancement over current treatments like semaglutide (Ozempic/Wegovy) which target one receptor, and tirzepatide (Mounjaro) which targets two.
Retatrutide is currently in Phase 3 clinical trials. It is expected to seek regulatory approval from the MHRA (UK) and EMA (Europe) following completion of these trials. A realistic timeline for UK availability is 2027-2028, though this depends on trial outcomes and regulatory review timelines.
Mounjaro (tirzepatide) is a dual-action GLP-1/GIP agonist that achieves up to 22% weight loss. Retatrutide adds a third target — the glucagon receptor — which increases energy expenditure and fat burning. Phase 2 trials showed retatrutide achieving up to 24% weight loss in 48 weeks, with the potential for even greater results in longer trials.
Yes. Evernu is committed to offering retatrutide to eligible patients as soon as it receives UK regulatory approval and becomes available through licensed UK pharmacies. Our clinical team is actively monitoring the trial data and regulatory process.
Yes. You can join our waiting list to be notified as soon as retatrutide becomes available through Evernu. We will keep you updated on trial results, regulatory milestones, and expected availability dates.
Not necessarily. Different patients respond differently to different medications. Mounjaro and Wegovy will continue to be effective treatments for many patients. Retatrutide will be an additional option, particularly for patients who may benefit from the triple-action mechanism or who have not achieved their goals with existing treatments.
More than medication.
A complete lifestyle companion.
Personalised meal plans, guided workouts, hydration tracking and real-time progress — all designed to maximise your results.
Interested in Weight Loss Treatment?
Start your journey today with our clinically proven programme, and be first in line when retatrutide becomes available.
Start Free Assessment